DIA
Drug Information Association Logo

The 7th DIA China Annual Meeting

May 24 2015 8:30AM - May 27 2015 5:00PM | Shanghai International Convention Center No. 2727, Riverside Avenue Pudong 200120 Shanghai China

« Back to Listing

Overview 

The 7th DIA China Annual Meeting: "Innovation and Convergence - Building a Sustainable R&D Ecosystem" will be held at Shanghai International Convention Center (SHICC) on May 24-27, 2015. This is the largest multidisciplinary event DIA has in Asia, bringing together a global network of professionals to foster innovation and promote convergence in building a sustainable R&D ecosystem. This will lead to the accelerated development of safe and effective medical products and therapies for patients. The 7th DIA China Annual Meeting provides a great platform and excellent networking opportunities to share knowledge, experiences, successes, and solutions, and to build new relationships. In particular, DIA China 2015 will make a conscious effort to address the needs of domestic drug companies with global aspiration and to approach medical product development from a multidisciplinary perspective.

For more details, Please go to http://en15975.eventdove.com/

Contact Information 

For exhibition, advertising and hosting inquiry, please contact:
Jean XU: jxu@kellencompany.com, or Sofie Peeters: speeters@kellencompany.com
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
dia@diachina.org
Tel: +86 10 5704 2650

Program Committee 

Previous Next

Agenda  

Tutorials Sunday, May 24, 2015

  • 8:30AM - 9:30AM (China Standard Time)

    Workshop 1: Essential Biostatistics Concepts Made Easy
  • 8:30AM - 5:30PM (China Standard Time)

    Workshop 2: How to Complete a CDISC - Compliant CRF Annotation
  • 8:30AM - 5:30PM (China Standard Time)

    Workshop 3: Exploring Medical Communications Services to Support Patient Care Decisions
  • 8:30AM - 5:30PM (China Standard Time)

    Workshop 4: Lean: Innovative Approaches for Authoring Clinical Regulatory Documents

Day 1 Sunday, May 24, 2015

  • 8:30AM - 9:30AM (China Standard Time)

    Session 0402 Application of Bayesian Methods for Clinical Trials


    Session Chair(s):

    • Bingming Yi
      Director
      GSK, China

    Speaker(s):

    • Maximizing Return on Investment in Designing Phase II Clinical Trials
      Cong Chen, PhD
      Director
      Merck & Co., Inc., United States
    • A Bayesian prediction model between biomarker and clinical endpoint for dichotomous variables
      Yang Song
      Sr. Prin. Scientist, Biostatistics
      MSD, China
    • A case study for a Bayesian approach to the assessment of safety for biosimilar and its application to bridging study (CN&EN)
      Jerry Wang
      Pfizer, United States
  • 8:30AM - 9:30AM (China Standard Time)

    Session 0502 Effective Risk Management


    Session Chair(s):

    • Joy Li
      Director of pharmacovigilance and medical information
      BMS China R&D, China

    Speaker(s):

    • Stephen Smith, MA
      Senior Director, Patient Value
      Medidata Solutions Worldwide, United States
    • Evolution of Risk Management in Peri-Approval & Observational Research
      Hady Khoury
      VP Global Head
      ICON, USA, China
    • Safety Use in the New Diabetes Medicines and Drug Safety Management in Hospital
      Yiming Li
      Professor
      Huashan Hospital of Fudan University, China
  • 8:30AM - 9:30AM (China Standard Time)

    Session 0602 Managing Post-Approval CMC Changes in China and the US - II


    Session Chair(s):

    • Melly Lin
      Regulatory Manager
      Roche (China) Holding Ltd., China
    • Chi-Wan Chen, PhD
      Executive Director, Global CMC
      Pfizer Inc, United States

    Speaker(s):

    • Experience Sharing on Multiple Sites for Biologics in Taiwan
      Jofeng Chi
      Section Chief, Taiwan
      Food and Drug Administration Ministry of Health and Welfare, China
    • Managing post-approval changes for chemical drugs-case studies (EN&CN)
      Chi-Wan Chen, PhD
      Executive Director, Global CMC
      Pfizer Inc, United States
    • Managing Post-Approval CMC Changes for Biologics in a Global Market – Case Studies (EN&CN)
      Andrew Chang
      Vice President,Quality and Regulatory Compliance, Product Supply Quality
      Novo Nordisk, USA, China
  • 8:30AM - 9:30AM (China Standard Time)

    Session 0802 Breakthrough of Innovative Cancer Therapies and Impact on Local Innovation in China


    Session Chair(s):

    • Jian Peng
      Sanofi R&D China, China
    • No-image Xianping LU
      CEO & Chief Scientific Officer
      Chipscreen Biosciences, Ltd., Shenzhen, China

    Speaker(s):

    • Clinical Progress in Innovation Treatment of Lung Cancer.pdf
      Caicun ZHOU
      Director
      Tongji University, China
    • Advanced Translational Medicines in Oncology Drug Discovery and Development
      Jimmy Jin
      TSU AsiaPacific, Sanofi R&D, China
    • Xianping LU
      CEO & Chief Scientific Officer
      Chipscreen Biosciences, Ltd., Shenzhen, China
    • Jason Yang
      Senior Vice President, Clinical Development
      BeiGene Co., Ltd, China
    • Zhaolong Gong
      CEO
      3D Medicines, China
    • Developme Strategy& Innovative Pipeline
      Shunjiang Yu
      Director, Medical
      Jiangsu Hengrui Medicine Co., Ltd, China, China
  • 8:30AM - 9:30AM (China Standard Time)

    EMBRACE THE DYNAMIC ENVIRONMENTAL CHANGE INNOVATIONS LEAD TO NEW OPPORTUNITIES AND SOLUTIONS


    Session Chair(s):

    • Mary McKenna, MSc
      Associate Director, US & Frankfurt Regional Head - Clinical Electronic Document
      Sanofi, United States

    EMBRACE THE DYNAMIC ENVIRONMENTAL CHANGE INNOVATIONS LEAD TO NEW OPPORTUNITIES AND SOLUTIONS

    Speaker(s):

    • eCTD in China Implications for its adoption for medical writers and regulatory strategists in China and beyond
      Shenqi Ji
      Pfizer R&D, China
    • A transparent world how the growing commitment to sharing clinical trial information, results and data with the broader public is chan
      Selvastine Selvaraj
      Parexel International (India) Pvt Ltd, India
    • Tools of the trade How shifting from a document-centric to a content-focused mindset and toolset supports the standards, speed and sco
      Fredericksen Steffen
      Founder, Chief Science Officer
      DITA Exchange, Denmark, China
  • 8:30AM - 9:30AM (China Standard Time)

    Session 1202 Public/Private Partnerships to Accelerate Product Development for the Developing World


    Session Chair(s):

    • Carol Zhu
      Senior Program Officer of R&D
      Bill & Melinda Gates Foundation, China Office, China

    Speaker(s):

    • Jialing Dai
      Chief Editor
      PharmaDJ, China
    • Mingshu Ma
      Journalist
      HealthCare Executive, China
    • Donglei Mao, MS
      Journalist / Chief Medicial Director
      Journal of China Prescription Drug, China
    • Zheng Zhao
      Assistant, Center for Pharmaceutical Information and Engineering Research
      Center for Pharmaceutical Information and Engineering Research, Peking Universit, China
    • Invest for the Poor – What We Do at Gates Foundation to Play a Role
      Yinuo Li
      Partner
      Bill & Melinda Gates Foundation, China Office, China
    • Global Public Goods Need for new models to accelerate product development
      Bernhard Schwartlander
      Representative
      WHO China Office, China
  • 8:30AM - 9:30AM (China Standard Time)

    Session 0704 Development of Biosimilars in China: Interpretation of Biosimilar Guidance, Opportunities and Challenges - II


    Session Chair(s):

    • Joe Zhang
      Shanghai CP Guojian Pharmaceutical Co.,Ltd, China

    Speaker(s):

    • Weidong Jiang
      Chief Strategy Officer and Senior Vice President
      Henlius, China
    • Science Based BiosimilarRegulatory Pathway
      Irene Deng
      Head of Regulatory China
      Roche Pharmaceuticals Ltd., China
    • Biosimilar from Similar to Highly Similar
      Cindy Xu
      Henlius, China
  • 8:30AM - 9:30AM (China Standard Time)

    Clinical Development Plan for DAA on HCV-overview


    Session Chair(s):

    • Jessica Liu
      VP Clinical Development, General Medicine BU, Asia-Pacific Region
      INC Research, China

    Clinical Development Plan for DAA on HCV-overview

    Speaker(s):

    • Hepatitis C Status and Umet Needs WEI-Shanghai 20150526-new
      Lai Wei
      PKU People's Hospital, China
    • DIA-Clinical Development Plan for DAA on HCV-overview
      Jinzi Wu
      Ascletis BioScience Co., Ltd., China
    • DIA HCV DAA in China 20150526
      Tao Wang
      CFDA, China
  • 8:30AM - 9:30AM (China Standard Time)

    Session 0904 Technology Leads to New Opportunities for Meeting Customer Medical Information Needs


    Session Chair(s):

    • No-image Stacey M. Fung, PharmD
      Associate Director, Medical Communications
      Genentech, A Member of the Roche Group, United States

    Speaker(s):

    • Different Roles Using a Globalized MI System for Internal and External Customers
      Jack Yu
      Medical Information Manager, Medical Communication
      Roche, China
    • Technology Leads to New Opportunities for Meeting Customer Medical Information Needs (EN&CN)
      Stacey M. Fung, PharmD
      Associate Director, Medical Communications
      Genentech, A Member of the Roche Group, United States
    • Does size really matter (EN&CN)
      Wendy Huo
      Associate Director
      Pfizer China Business Technology, China
  • 8:30AM - 9:30AM (China Standard Time)

    Session 1004 Newer Than New-Innovations to Create New Health Solutions


    Session Chair(s):

    • Yiwu He
      Senior program officer, Global Health
      Bill & Melinda Gates Foundation, China

    Speaker(s):

    • Why are we still working on HIV vaccines
      Shan Lu
      Professo
      University of Massachusetts Medical School, USA, China
    • Edward Lin
      Chief Medical Officer
      P4 Medicine Institute, Seattle, USA, China
    • A Practical View on Precision Immunotherapy Engineering the Body’s Immune System to Treat Cancer
      Xiangjun Zhou
      Chief Scientific Officer
      SYZ Cell Therapy Co., China
  • 8:30AM - 9:30AM (China Standard Time)

    Session 0505 Post Marketing Safety Surveillance


    Session Chair(s):

    • Ivy Wang
      Associate Director, Safety Surveillance & Risk Management
      Pfizer, China

    Speaker(s):

    • Evidence Triggered and Evidence Based - Thinking of Postmarking Drug Safety Issues (CN&EN)
      Dayou WANG
      Huashan Hospital, Fudan University, China
    • Signal Detection during Post-marketing Surveillance(CN&EN)
      Howe Li
      CMO
      Tigermed, China
  • 8:30AM - 9:30AM (China Standard Time)

    Session 0605 ChP Townhall


    Session Chair(s):

    • No-image Yi REN, PhD, MBA
      General Manager
      Nanjing Medichem Bio-Pharmaceutical Development Co. , China

    Speaker(s):

    • Wei Zhang
      CFDA, China
    • Change of ChP 2015 and Future Direction
      Wei Zhang
      Director General, Department of Drug Registration, CFDA, China
      CFDA, China, China
    • USP&PDG_Pharmacopeial Discussion Group’s Perspective on Harmonization (EN&CN)
      Kevin Cao
      User Relationship Management, USP
      USP, China
    • Industry’s Perspective on Pharmacopeia Harmonization and collaboration
      Melly Lin
      Regulatory Manager
      Roche (China) Holding Ltd., China
  • 8:30AM - 9:30AM (China Standard Time)

    Session 0705 Detection and Evaluation of Immunogenicity of Biologics


    Session Chair(s):

    • Haifeng Song
      Professor
      Academy of Military Medical Sciences, China

    Speaker(s):

    • Recommendations from the AAPS LBABFG Biosimilars Action Program Committee on the Development and Validation of ADA assays for Biosimilars
      Michael Anderson
      President and Chief Scientific Officer
      Biologics Development Services, LLC, USA, China
    • Eric Liang
      Group Manager/CNIBR DMPK-Biologics
      Novartis, China
    • Important Consideration in Anti-drug Antibody Assay Development
      Dongbei Li
      Senior Director, Bioanalytical services
      Wuxi AppTec, China
  • 8:30AM - 9:30AM (China Standard Time)

    Regulatory Writing CTD, ICH E3-compliant CSR, andChina Submission Dossier Preparation


    Session Chair(s):

    • Hongbo Zhu
      Head Medical Writing
      Boehringer Ingelheim International Trading (Shanghai) Co., Ltd. , China

    Regulatory Writing CTD, ICH E3-compliant CSR, andChina Submission Dossier Preparation

    Speaker(s):

    • Zhimin YANG, MD
      Deputy Director, Senior Reviewer on Clinical Trials
      Division I of Clinical Trials for Pharmaceuticals, CDE, CFDA, China
    • The RegulatoryMedical Writer’s Role in CTD Preparation
      Sybille M Eibert
      Senior Medical Writer / Teamleader
      Boehringer Ingelheimpharma Gmbh & Co. KG, Germany
    • Regulatory Writing CTD, ICH E3-compliant CSR, andChina Submission Dossier Preparation
      Helle-Mai Gawrylewski
      Senior Director, Medical Writing
      Janssen Research & Development, LLC, United States
  • 8:30AM - 9:30AM (China Standard Time)

    Session 1005 Generic Drug Forum - I - Global Requirements and Regulatory Initiatives


    Session Chair(s):

    • Shaoyu Chen, JD
      Managing Director, China Food and Drug Practice; Partner
      Covington & Burling LLP, China

    Speaker(s):

    • Xuejie Dou
      Senior Director, Quality
      Xinhua Pharmaceutical, China
    • U.S. Generic Drug Framework
      Keith Flanagan
      Director, and head of Office of Generic Drug Policy (OGDP)
      Office of Generic Drugs, CDER, FDA, China
    • Chia-Ling Hsiao
      PK Reviewer
      Center for Drug Evaluation, Taiwan
    • Toru Yamaguchi
      Reviewer Pharmacist
      Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Day 2 Monday, May 25, 2015

  • 1:30PM - 5:30PM (China Standard Time)

    Opening Plenary Session

    Speaker(s):

    • Lin Yuan
      General Director
      CFDA, China

Day 3 Tuesday, May 26, 2015

  • 8:30AM - 10:00AM (China Standard Time)

    Session 0101 Successful Stories of Bringing Innovative Product into China Market


    Session Chair(s):

    • Wendy Yan
      Senior Vice President, Head of Regulatory/Affairs
      BeiGene (Beijing) Co., Ltd., China
    • No-image Xianping LU
      CEO & Chief Scientific Officer
      Chipscreen Biosciences, Ltd., Shenzhen, China

    Speaker(s):

    • Yongzhong Wang
      Deputy General Manager
      Kanghong Pharmaceutical, China
  • 8:30AM - 10:00AM (China Standard Time)

    THE RESPONSIBILITIES TO SPEED UP CLINICAL TRIALS


    Session Chair(s):

    • No-image Shuting LI, MD
      Director, GCP Center
      Cancer Institute & Hospital, Chinese Academy of Medical Sciences, China

    THE RESPONSIBILITIES TO SPEED UP CLINICAL TRIALS

    Speaker(s):

    • George Guo
      Global Monitoring Operation Country Head
      Novartis Pharmaceuticals, China
    • Speed Site Start-up
      Winnie Xu
      AD
      Quintiles Medical Development (Shanghai) Co. Ltd, China
    • Huanling Wang
      Vice Director, Clinical Pharmacology Research Center
      Peking Union Medical College Hospital, China
    • YongChuan Chen
      Xinan Hospital of Third military medical university , China
    • Zhiqiang Ning
      VP R&D
      Chipscreen Biosciences Ltd., China
    • Tim Shi
      Executive Director
      GlobalMD, United States
  • 8:30AM - 10:00AM (China Standard Time)

    Session 0401 Statistical Methods for Oncology Clinical Trials


    Session Chair(s):

    • Ouhong Wang, PhD
      Director
      Amgen Inc., United States

    Speaker(s):

    • An Adaptive Seamless Phase IIIII Design for Oncology Trials with Subpopulation Selection Using Correlated Survival Endpoints
      Jerry Wu
      Manager, Biostatistics
      Amgen, China
    • Flexible Modelling of Survival Curves for Censored Data in Oncology Trial
      Steve Su
      Senior Biostatistician, Statistics and Programmin
      Covance, Australia, China
    • Interval-censoring and its applications to oncology endpoint
      Chao Zhu
      Lilly Suzhou Pharmaceutical Co. Ltd., China, China
    • Statistical Considerations in Analyzing Disease with Recurrent Events
      Fan Xia
      Roche, China
  • 8:30AM - 10:00AM (China Standard Time)

    Session 0501 Drug Safety in Clinical Development – Benefit / Risk Based Decision


    Session Chair(s):

    • Yuan Meng
      Director, Associate Safety Risk Lead (Associate SR
      Pfizer (China) Research and Development Co.,Ltd, China

    Speaker(s):

    • Mason Shih
      Site Head, Drug Safety, Asia Pacific
      Genentech, a Member of Roche Group, China
    • Safety Surveillance& Risk Management in Drug Development
      Ayman Ayoub
      Senior Director, Senior Director, Disease Area Head Member of Pfizer Hepatic Inj
      Pfizer, UK, China
    • The Value of Drug Safety in Drug Development
      Mason Shih
      Genentech Inc., United States
  • 8:30AM - 10:00AM (China Standard Time)

    Session 0601 Managing Post-Approval CMC Changes in China and the US - I


    Session Chair(s):

    • Melly Lin
      Regulatory Manager
      Roche (China) Holding Ltd., China
    • Chi-Wan Chen, PhD
      Executive Director, Global CMC
      Pfizer Inc, United States

    Speaker(s):

    • Overview of Regulations and Guidelines on Post-Approval CMC Changes for Chemical Drugs in the U.S
      David LIN, PhD
      Senior Consultant
      Biologics Consulting Group, Inc., United States
    • Chi-Wan Chen, PhD
      Executive Director, Global CMC
      Pfizer Inc, United States
    • China Post-Overview of Regulations and Guidelines on Post- Approval CMC Changes for Biotechnological Products in U.S.
      Duu-gong Wu
      Director
      Pharmaceutical Product Development, USA, China
    • Post-approval CMC changes in China
      Zhen Chen
      Professor
      Medicine College, Zhengzhou University, China
  • 8:30AM - 10:00AM (China Standard Time)

    Session 0701 New Trend/Technology in Biologic Development


    Session Chair(s):

    • Chengbin Wu
      Chief Scientific Officer, President of R&D
      Shanghai CP Guojian Pharmaceuticals Co. Ltd., China

    Speaker(s):

    • Bispecific Antibody TCell Engager for Cancer Immunotherapy
      Mingqiang Zhang
      General Manager, Corporate VP of R&D
      Amgen BioPharmaceutical R&D (Shanghai) Co., Ltd, China
    • Antibody Drug Discovery Develop Critical Assays for Novel Antibody Drugs
      Kang Li
      Head of Biologics
      BeiGene, China
    • Antibody Drug Discovery Develop Critical Assays for Novel Antibody Drugs
      Peter Luo
      Co-founder and Chief Executive Officer
      Adagene Inc., China
  • 8:30AM - 10:00AM (China Standard Time)

    Session 0801 Breakthrough by Innovative Disease Therapies


    Session Chair(s):

    • Xiaoxiang Chen
      Vice President
      Boehringer Ingelheim Shanghai Pharm. Co. Ltd, China

    Speaker(s):

    • Linong Ji
      ??,????
      People’s Hospital, Peking University, China
    • Overview Innovative Therapies in Year 2014 and Forecast of Year
      Charles Xie
      Head of clinical development, Greater China
      Boehringer Ingelheim, China
  • 8:30AM - 10:00AM (China Standard Time)

    Medical writing evolution and expansion from global to China, from the past to the future


    Session Chair(s):

    • Julia Cooper, PhD
      Vice President, Head of Global Medical Writing Services
      PAREXEL International, China

    Medical writing evolution and expansion from global to China, from the past to the future

    Speaker(s):

    • Medical Writing Evolution and Expansion in the Global Environment (EN&CN)
      Thomas Martin Schindler, PhD
      Head Medical Writing Europe
      Boehringer Ingelheim Pharma GmbH & Co.KG, Germany
    • 0901-3_Roselynn Tien_Target Profile for a Medical Writer in China How to Develop a Good Medical Writer in China
      Nan Wang
      Scientific Medical Writer, Global Medical Writing
      Bayer, China
    • Target Profile for a Medical Writer in China How to Develop a Good Medical Writer in China
      Roselynn Tien
      Director, Medical Writing Services Asia Pacific Director, Global Resource Manage
      PAREXEL,Singapore, China
  • 8:30AM - 10:00AM (China Standard Time)

    Session 1001 Developing New Drugs from Traditional Chinese Medicine for Unmet Public Health Needs (Part I)


    Session Chair(s):

    • Weiguo Jia
      Lab Director, Associate Professor
      Centre for Brain Health, University of British Columbia, Canada, China

    Speaker(s):

    • Evolution of Herbal Medicines to Botanical Drugs Opportunities and Challenges (EN&CN)
      Jinhui Dou
      Pharmacologist, Botanical Review Team Office of Pharmaceutical Science
      CDER, FDA, China
    • Selection of Quality Raw Herbsto Build a Solid Foundation for Formulated Chinese Medicine Products (EN&CN)
      Yuming Chi
      Director
      Tongreng Tang Research Institute, Beijing, China
    • Long Cheng
      Professor, Director, Pharmaceutical Innovation and New Technology Research Offic
      China National Health Development Research Center, China
  • 8:30AM - 10:00AM (China Standard Time)

    INNOVATION: WHY SHOULD I CARE?


    Session Chair(s):

    • Qiang Lai
      Drug Executive, China
  • 8:30AM - 10:00AM (China Standard Time)

    RISK BASED SAFETY MONITORING
  • 8:30AM - 10:00AM (China Standard Time)

    PATIENT AND THERAPEUTIC CENTRIC CLINICAL MATERIALS

    Speaker(s):

    • Christine Milligan
      Global Director
      Catalent Pharma Solutions, China
  • 10:30AM - 12:00PM (China Standard Time)

    General principles on planningdesigning Multi-Regional Clinical Trials E17


    Session Chair(s):

    • No-image Yoshiaki Uyama, PhD
      Director, Office of Medical Informatics and Epidemiology
      Pharmaceuticals and Medical Devices Agency (PMDA), Japan

    General principles on planningdesigning Multi-Regional Clinical Trials E17

    Speaker(s):

    • Impacts of E17 Guideline for Drug Review and Approval in Taiwan
      Lih-Jiuan HSU
      Medical Reviewer
      Center for Drug Evaluation, Taiwan
    • Global Drug Development Impact of ICH E17 Guideline_An Industry Perspective
      Patrick K Brady, PharmD
      Science and Regulatory Affairs
      Pharmaceutical Research and Manufacturers of America (PhRMA) , United States
  • 10:30AM - 12:00PM (China Standard Time)

    Opening


    Session Chair(s):

    • No-image Shuting LI, MD
      Director, GCP Center
      Cancer Institute & Hospital, Chinese Academy of Medical Sciences, China

    Opening

    Speaker(s):

    • George Guo
      Global Monitoring Operation Country Head
      Novartis Pharmaceuticals, China
    • Winnie Xu
      AD
      Quintiles Medical Development (Shanghai) Co. Ltd, China
    • Huanling Wang
      Vice Director, Clinical Pharmacology Research Center
      Peking Union Medical College Hospital, China
    • What will be reviewed in multicenter ethical review units should review what?
      YongChuan Chen
      Xinan Hospital of Third military medical university , China
    • Zhiqiang Ning
      VP R&D
      Chipscreen Biosciences Ltd., China
    • The feasibility of center ethical review implementation in China
      Tim Shi
      Executive Director
      GlobalMD, United States
  • 10:30AM - 12:00PM (China Standard Time)

    Session 0702 Safety Evaluation of New Types of Antibodies


    Session Chair(s):

    • Jufeng Wang
      Director
      National Institutes for Food and Drug Control, China

    Speaker(s):

    • Current Challenges and Opportunities in Preclinical Safety Assessment of Multi-specific Biologics
      Hong Wang
      Senior Scientist/Oncology Therapeutic Area Leader
      Genentech, a Member of Roche Group, China
    • Clinical Safety Evaluation of New types of Antibodies
      Yan Huo
      Director of General Toxicology, NCSED
      CFDA, China
    • Preclinical Development for Monoclonal Antibody (mAb) Current Practice and Future Direction
      James Yan
      Executive Director & Site Lead
      Covance, China
  • 10:30AM - 12:00PM (China Standard Time)

    TCM Bioinformatics and Post-Metabolism Compounds as Innovative Approaches for New Drug Development


    Session Chair(s):

    • Jinhui Dou
      Pharmacologist, Botanical Review Team Office of Pharmaceutical Science
      CDER, FDA, China

    TCM Bioinformatics and Post-Metabolism Compounds as Innovative Approaches for New Drug Development

    Speaker(s):

    • Weiguo Jia
      Lab Director, Associate Professor
      Centre for Brain Health, University of British Columbia, Canada, China
    • 1002-2_Dennis Bashaw_Clinical Pharmacology Studies for Botanicals in Different Phases of New Drug Development.pdf
      Dennis Bashaw
      Director Office of Clinical Pharmacology
      US Food and Drug Administration, China
  • 10:30AM - 12:00PM (China Standard Time)

    CFDA Townhall

    Speaker(s):

    • Gongtao La
      CFDA, China
    • Maozhong Li
      CFDA, China
    • Jianan Wang
      CFDA, China
  • 1:30PM - 3:00PM (China Standard Time)

    Session 0703 Development of Biosimilars in China: Interpretation of Biosimilar Guidance, Opportunities and Challenges - I


    Session Chair(s):

    • Joe Zhang
      Shanghai CP Guojian Pharmaceutical Co.,Ltd, China

    Speaker(s):

    • EMA & Biosimilar update Trends and developments in marketing authorisation applications, scientific advice procedures and policies
      Evangelos Kotzagiorgis
      Scientific Administrator, Quality of Medicines, Human Medicines Evaluation Div
      European Medicine Agency, United Kingdom
    • Global mAb Biosimilar Industry Challenges and Opportunities from Policy to Reality
      Joe Zhou
      CEO
      Genor BioPharm, Walvax Bio Group, China
  • 1:30PM - 3:00PM (China Standard Time)

    Slides for diabetes session


    Session Chair(s):

    • Yan Gong
      Senior Global Clinical Program Lead, Corporate Division of Medicine
      Boehringer-Ingelheim, Germany, China
    • No-image Huaqiong SHEN, MD, PhD
      Chief Medical Officer
      Jiangsu Hengrui Medicine Co., Ltd., China

    Slides for diabetes session

    Speaker(s):

    • Diabetes Treatment - Insulin and GLP-1
      Kezhou Zhang
      Vice President, Clinical & Medical & Regulatory
      Novo Nordisk (China) Pharmaceuticals Co. Ltd., China
    • Recent advancement of drug development in diabetes - synthetic chemical entity
      ShuHua SHANG
      Clinical Research Director
      sanofi, China
    • Yan Gong
      Senior Global Clinical Program Lead, Corporate Division of Medicine
      Boehringer-Ingelheim, Germany, China
    • Status Quo, Challenges and Opportunities for Domestic Companies in Diabetes Therapies
      Eric Hua
      Overseas Clinical Project Manager, Clinical Operations
      Gan & Lee Pharmaceuticals, China
    • Pipeline in Diabetes – From the Industrial Perspective (EN&CN)
      Chengyu Guan
      Medical Director
      Jiangsu Hengrui Medicine Co., Ltd, China, China
  • 1:30PM - 3:00PM (China Standard Time)

    Why is professional medical writer needed in boosting scientific publication in China


    Session Chair(s):

    • Xiaoling Wang
      Sr. Manager
      Clinical Documentation, Sanofi R&D, China

    Why is professional medical writer needed in boosting scientific publication in China

    Speaker(s):

    • Ethical Publication andMedical Writer’s Role (EN&CN)
      Yuko Kojima, RPh
      Director, Asia Pacific Medical Communications
      Eli Lilly Japan K.K., Japan
    • Why it is important to publish data from China and how to publish successfully
      Rui Yang
      Senior Scientific Communication Manager
      Novo Nordisk, China
    • Clinical Trial DataSharing A Publisher’s Perspective
      Ella Chen
      Business Development Manager
      BMJ China, China
  • 1:30PM - 3:00PM (China Standard Time)

    Session 1003 WHO Pre-Qualification and Global Collaborations: Running Pharmaceutical Business Beyond China


    Session Chair(s):

    • Yiwu He
      Senior program officer, Global Health
      Bill & Melinda Gates Foundation, China

    Speaker(s):

    • Richard Wang
      Chairman
      Yichang Humanwell Pharmaceuticals, China
    • 1003-1_ Lance Rodewald_WHO Vaccine Prequalification Program for High Burden Diseases.pdf
      Lance Rodewald
      Expanded Program on Immunization Team Lead
      China Country Office, World Health Organization, China
    • Yuzhong Tang
      Humanwell Pharma Afrique S.A. (Mali), China
    • The National Center for Advancing Translational Sciences
      Anton Simeonov
      Acting Scientific Director, National Center for Advancing Translational
      Sciences (NCATS), National Institutes of Health, China
    • Richard Wang
      Chairman
      Yichang Humanwell Pharmaceuticals, China

Day 4 Wednesday, May 27, 2015

  • 8:30AM - 10:00AM (China Standard Time)

    Session 0105 How Far Away is the Innovative Medicine to China Patients? - I


    Session Chair(s):

    • No-image Zhiang WU, PhD
      Shenyang Pharmaceutical University, China

    Speaker(s):

    • The Plight for New Drugs to Achieve Their Values
      Ying Shao
      Vice President and Director of R&D Center
      Shanghai Fosun Pharmaceutical (Group) Co., Ltd.., China
    • Innovation, Risk and Recognition the Political Sociology for New Drugs
      Yinglian Hu
      Associate Professor
      Chinese Academy of Governance, China
    • Ruilin SONG, JD
      ExecutivePresident
      Chinese Pharmaceutical Association, China
    • Qi Zhang
      CFDA, China
  • 8:30AM - 10:00AM (China Standard Time)

    Introductory slide on CDP


    Session Chair(s):

    • Sunny Zhu
      Global Clinical Lead,
      Bayer Healthcare , China

    Introductory slide on CDP

    Speaker(s):

    • Holistic Approaches to Biopharmaceutical Product Development
      Theo J Hoofwijk
      Executive Director, Global Strategic Drug Development
      Center for Integrated Drug Development, Quintiles, Netherlands, China
    • Clinical Development Plan Considerations for China Local Innovations (EN&CN)
      Ning Xu
      Executive Vice President
      ZaiLaboratory, China
  • 8:30AM - 10:00AM (China Standard Time)

    Session 0405 Evolving CDM Role in Clinical Trials


    Session Chair(s):

    • Li Ding
      Senior Director, Trial Operation China Site Head and AP Coordinator
      Sanofi, China

    Speaker(s):

    • Lin Yuan
      General Director
      CFDA, China
    • CDM Evolvement Reveiw
      Jessie Chen
      Senior Manager
      Pfizer(China)Research Devevlopment Co. Ltd., China
    • Evolving CDM Role Enabled by Technology – EDC
      Rong Ran
      Chengdu Brightech-Magnsoft Clinical Researches, China
    • Evolvement driven by diversified business model - outsourcing operation model
      John Tang
      Senior Director, Clinical Data Mangement
      Quintiles, China
    • Evolvement with expertise enhancement in China_Contribution from China to the world
      Yue Zhang
      Global Data Management Specialist Lead
      MSD (Shanghai) Pharmaceuticals Consultancy Co. Ltd, Beijing, China
  • 8:30AM - 10:00AM (China Standard Time)

    Medical Affairs overview for DIA


    Session Chair(s):

    • Victoria Elegant, MD, FFPM
      Vice President, Medical & Regulatory Affairs, Asia- Pacific
      Baxter Healthcare , China

    Medical Affairs overview for DIA

    Speaker(s):

    • Gaoqiang Xie
      program manager
      Peking University Clinical Research Institute, China
    • Aligning Medical Strategy to Provide Best Outcomes
      Alexander Condoleon
      Sanofi China, China
    • Innovation on Delivery of the Latest Medical Knowledge to HCPs'
      Frances Chang
      Vice President, Medical Affairs
      Roche, China
    • Harris Xia
      Associate Director
      AstraZeneca, China
  • 8:30AM - 10:00AM (China Standard Time)

    Bringing Drug to Patients Sooner: Parallel Global Clinical Development in the Age of Personalized Medicine

    Speaker(s):

    • Honggang Bi
      Covance Inc.
      Covance, China
    • Peter Varney
      Global Vice President Alliance Management
      Covance Inc., China
  • 8:30AM - 10:00AM (China Standard Time)

    PARTNERSHIP STRATEGIES AND CREATIVE FRAMEWORKS IN THE NEW ERA

    Speaker(s):

    • Shunjiang Yu
      Director, Medical
      Jiangsu Hengrui Medicine Co., Ltd, China, China
  • 10:30AM - 12:00PM (China Standard Time)

    Session 0106 How Far Away is the Innovative Medicine to China Patients? - II


    Session Chair(s):

    • No-image Zhiang WU, PhD
      Shenyang Pharmaceutical University, China

    Speaker(s):

    • New Drugs and Rational Medication
      Luwen Shi
      Professor
      Peking University School of Pharmaceutical Sciences, China
  • 10:30AM - 12:00PM (China Standard Time)

    Session 0306 Clinical Science - II - IMCT Latest Guidance: Population PK Value in Development


    Session Chair(s):

    • No-image Paul Dai, MD
      Senior Director, Regional Head of ICRO AMAC & Greater China Region
      Beijing Novartis Pharma Co., Ltd., China

    Speaker(s):

    • Early Phase Development Design Strategy3 DIA7 Bashaw (NXPowerLite Copy)
      Dennis Bashaw
      Director Office of Clinical Pharmacology
      US Food and Drug Administration, China
    • Early phase development strategy & value of model based drug development
      Hartmut Blode
      Head of Clinical Pharmacology Asia/ Primary Care
      Bayer Healthcare Co.,Ltd., China
    • Considerations for First-in-Man (FIM) Studies
      Peiming Ma
      Senior Director, Clinical Pharmacology, R&D Center
      GSK China, China
  • 10:30AM - 12:00PM (China Standard Time)

    Session 0406 Quality and Integrity of Clinical Trial Data


    Session Chair(s):

    • Daniel Liu, PhD
      Chief Scientific Officer
      Beijing Clinical Service Center, China

    Speaker(s):

    • Qin Huang, PhD
      Deputy Director, Office of Biostatistics
      Center For Drug Evaluation, CFDA, China
    • An Emerging Regulatory Landscape Impacting Quality and Integrity of Clinical Data Submission Trial Master File
      Daniel Liu, PhD
      Chief Scientific Officer
      Beijing Clinical Service Center, China
    • Summary level clinical site data for data integrity review and inspection planning in NDA and BLA submission
      Jingwei Gao
      Regional Head,Regional Statistical Programming – Pan Asia META
      Boehringer Ingelheim (China) Investment Co., Ltd., China
  • 10:30AM - 12:00PM (China Standard Time)

    Session 0506 Active Safety Surveillance


    Session Chair(s):

    • Min Chen
      Former Director of Pharmacovigilance, Office of Surveillance and Epidemiology
      CDER, FDA, China

    Speaker(s):

    • Dan Wang
      CFDA, China
    • YUAN Yao
      Merck Serono, China
    • Overview of US postmarketing (CN&EN)
      Min Chen
      Former Director of Pharmacovigilance, Office of Surveillance and Epidemiology
      CDER, FDA, China
    • Active_Surveillance_Songlin_Xue_DIA_China_2015 (CN&EN)
      Songlin Xue
      Executive Vice President, Head of Global Pharmacovigilance
      Astellas, China
  • 10:30AM - 12:00PM (China Standard Time)

    Trans Celerate Quality Management System Initiative (EN&CN)


    Session Chair(s):

    • Deborah Driscoll, MS
      Vice President, Quality Assurance, Medical Division
      Pfizer Inc, United States

    Trans Celerate Quality Management System Initiative (EN&CN)

    Speaker(s):

    • Ann Meeker-O'Connell, MS
      Head, Risk Management and External Engagement, Bioresearch Quality & Compliance
      Janssen Pharmaceuticals, Inc., United States
    • Trial-Level Quality approach highlighting TransCelerate’s model approach to RBM (EN&CN).pdf
      Brett Wilson
      Associate Director
      Bristol-Myers Squibb Company, Canada
    • Gongtao Lan
      CFDA - Registration, China
    • Jianan Wang
      Assistant Pharmacist
      CCD, CFDA, China
  • 10:30AM - 12:00PM (China Standard Time)

    Session 1006 Generic Drug Forum - II - Product Development for Quality Consistency


    Session Chair(s):

    • No-image Yi REN, PhD, MBA
      General Manager
      Nanjing Medichem Bio-Pharmaceutical Development Co. , China
    • No-image Jane Y. Cai, PhD
      Director, DIA China
      DIA (Beijing) Healthcare Information Consulting Ltd., China

    Speaker(s):

    • Generic reevaluation DIA meeting (EN&CN)
      Xinsheng Sun
      Director
      China Quality Association for Pharmaceuticals(CQAP), China
    • 1006-2_BingLi_Scientific and Regulatory Considerations for Establishing Bioequivalence of Generic Drug Products in USA (EN&CN).pdf
      Bing Li
      Vice President
      American Chinese Pharmaceutical Association, USA, China
    • Considerations for OTC Development For Emerging Markets (EN&CN)
      Chao Ye, PhD
      Associate Director, Research and Development, OTC
      Johnson & Johnson China, China
  • 10:30AM - 12:00PM (China Standard Time)

    Pharmaceutical Innovation in China


    Session Chair(s):

    • Dan Zhang, MD, MBA, MPH, MS
      Chairman & CEO
      Fountain Medical Development Ltd., United States

    Pharmaceutical Innovation in China

    Speaker(s):

    • Honggang Bi
      Covance Inc.
      Covance, China
    • Xiaoning Guo
      Program Director
      Covance, China
    • Beatriz Rocha
      Executive Director, Head of Clinical Global Regulatory Affairs Strategy
      Covance Inc, China
    • John Oyler
      CEO
      Beigen, China
    • Henry Sun
      Vice President
      Tasly Holding Group, China
    • Pharmaceutical Innovation in China
      Fangning Zhang
      McKinsey & Company, China
  • 10:30AM - 12:00PM (China Standard Time)

    Special Session Brain Storm - Discussion in Depth of China SMO Practice


    Session Chair(s):

    • No-image Shuting LI, MD
      Director, GCP Center
      Cancer Institute & Hospital, Chinese Academy of Medical Sciences, China
    • Luke Lu
      Eli Lilly, China

    Speaker(s):

    • Murray M. Lumpkin, MD, MSc
      Deputy Director, Regulatory Affairs, Lead Global Regulatory Systems Initiatives
      Bill and Melinda Gates Foundation, United States
    • Robert Urban
      -
      Johnson&Johnson Innovation Center, USA, China
    • Xianglin Zhang
      President
      Shenyang Pharmaceutical University, China
    • Leon ZHANG
      SMO, China
    • Mingli Xu
      General Manager
      Beijing HMO Medicine Technology Co.,Ltd, China
    • Shuyan Chen
      Clinical Research Coordinator Associate Director
      Kun Tuo Medical Research & Development (Beijing) Co., Ltd., China
    • Xiaochun Cao
      General Manager
      Hangzhou Simo Co., Ltd., China
    • Cindy Lu
      Business Operation Management Manager
      Eli Lilly Company, China
    • Yu Li
      ??
      Medtronic (Shanghai) Management Co., Ltd.s, China
  • 1:30PM - 3:00PM (China Standard Time)

    Session 0107 How Overseas Production Site Inspection be Done Efficiently and Effectively


    Session Chair(s):

    • Haifeng Cao
      Merck, China

    Speaker(s):

    • Inspections the Global Challenge-EMA Perspective
      Evangelos Kotzagiorgis
      Scientific Administrator, Quality of Medicines, Human Medicines Evaluation Div
      European Medicine Agency, United Kingdom
    • Yuan Wang
      CFDA, China
    • Pfizer’s Experience on CFDA Overseas GMP Inspections
      Jie Li
      RA
      Pfizer Investment Co., Ltd, China
  • 1:30PM - 3:00PM (China Standard Time)

    Session 0307 Clinical Operation - Risk Based Monitoring


    Session Chair(s):

    • Vicky Chen
      Senior Director, Clinical Development, Greater China
      INC Research, China

    Speaker(s):

    • LiHua FENG
      Sr.CPrM
      AstraZeneca, China
    • TransCelerate Clinical Operations RBM
      Brett Wilson
      Associate Director
      Bristol-Myers Squibb Company, Canada
    • Elements Required for Successful CRO-Sponsor Collaboration to Execute RBM sent 05142015
      PJ Chen
      Executive Director, Area Head, North Asia Clinical Management
      PPD, China
  • 1:30PM - 3:00PM (China Standard Time)

    Session 0407 Statistics and Data Management Joint Session - The Collaboration of DM and Statistics - I


    Session Chair(s):

    • Carina Reinicke
      Regional Head of Clinical Data Management
      Boehringer Ingelheim Shanghai Pharmaceuticals Co, Ltd., China

    Speaker(s):

    • CRF Design to Meet Requirement of Statistical Analysis Plan
      HuaLong Sun
      Meta Clinical, China
    • Randomization in Clinical Trial - Implement, and Irregularity Handling
      Bob Yan
      Head of Biostatistics & Programming, Sanofi China
      Sanofi, China
    • Implementing Metrics Management for Improving Data Management and Statistics Analysis Performance in Clinical Trials
      Yazhong Deng, MBA
      Director, Clinical Data, Analysis and Reporting organization
      Covance Pharmaceutical Research and Development (Beijing) Co., Ltd., China
  • 1:30PM - 3:00PM (China Standard Time)

    Session 0507 Vaccine Safety and Risk Management


    Session Chair(s):

    • William Wan
      PV Head
      Baxter, China

    Speaker(s):

    • Dan Wang
      CFDA, China
    • Safety of Vaccine – from the CDC Perspective
      Dawei Liu
      Director, AEFI Surveillance,National Immunization Program
      Chinese Center for Disease Control & Prevention, China
    • Li Shi, PhD
      CEO; Specialist of National "Thousands of people plan"; Member of Wison Group
      Shanghai Zerun Biotechnology , China
  • 1:30PM - 3:00PM (China Standard Time)

    Session 0907 Site Management & SMO


    Session Chair(s):

    • Reako Ren
      Executive Director and Head of SMO Services
      WuXi Apptec., China

    Speaker(s):

    • Site Perspective on CRC Administration and SMO Development Trend
      Yanfei Liu
      Director, GCP Office
      Shanghai Fudan University Cancer Hospital, China
    • Fast Site Start-up and Patient Enrollment with CRC
      Maggie Gu
      Astrazeneca, China
    • Today and Future- China SMO Development TrendModel and Operation Experience Share
      Reako Ren
      Executive Director and Head of SMO Services
      WuXi Apptec., China
    • CRC's Role in Global Clinical Trial Experience Sharing of EMA Inspection in China
      George Guo
      Global Monitoring Operation Country Head
      Novartis Pharmaceuticals, China
  • 1:30PM - 3:00PM (China Standard Time)

    Chinese Pharmaceutical Companies - Where Are We, Where DoWe Need to Go, How Do We Get There


    Session Chair(s):

    • Lee Kang
      VP/General Manager, Achlis Group
      The Perrigo Company, China

    Chinese Pharmaceutical Companies - Where Are We, Where DoWe Need to Go, How Do We Get There

    Speaker(s):

    • Data Integrity - FDA's Perspective, DIA Shanghai
      Gang Wang
      U.S.FDA China Office, China
    • Lee Kang
      VP/General Manager, Achlis Group
      The Perrigo Company, China
  • 1:30PM - 3:00PM (China Standard Time)

    Session 1107 Chinese Pharma/Biotech from Local to Global: From Strategies to Tactics


    Session Chair(s):

    • Frank Chiu
      General Manager
      Boon Pharmaceutical Research, Ltd., China
    • Jimmy Zhang
      Vice President, Transactions Asia Pacific Innovation Center
      Johnson & Johnson, China

    Speaker(s):

    • Shoubai Chao
      Senior Vice President
      Astrazeneca BioVentures, China
    • Frank Jiang
      Vice President and Head of Asia Pacific R&D
      sanofi, China
    • Xueming Qian
      Founder, Chairman and CEO
      MabSpace Biosciences, China
    • GLOBAL VS LOCAL Made in China, Developing globally
      Yan Wu
      Head, Clinical Operation and Drug Safety
      Hutchison MediPharma, China
    • Conducting the China sponsored IND clinical trials in US
      James D Fan, MD
      Medical Director, Asia Pacific Region and Japan
      ICON Clinical Research Ltd., Singapore
    • Regulatory Strategic Approach to US Market for Chinese Pharmaceutical Companies
      Yao Yao
      Specially Invited Professor
      IED, CFDA, China
    • Frank Chiu
      General Manager
      Boon Pharmaceutical Research, Ltd., China
  • 1:30PM - 3:00PM (China Standard Time)

    Companion Diagnosticfor Precision Medicine


    Session Chair(s):

    • Jinjie Hu
      Senior Consultant
      Biologics Consulting Group, United States

    Companion Diagnosticfor Precision Medicine

    Speaker(s):

    • Changhua Chen
      -
      GCP CLINPLUS, China
    • Xiaomeng Liu
      -
      GCP Clinplus, China
    • Personalized Medicine The Role of Biomarker for Clinical Treatment Decision
      Zhiyang Zhang
      -
      3G Biotech, China
    • Regulatory Implications for Personalized Medicines and Companion Diagnostics
      James Creeden, DrMed, PhD
      Director Medical Science
      Roche (china) Ltd., China
    • Juanjuan An
      CFDA, China
  • 1:30PM - 5:30PM (China Standard Time)

    GENERIC DRUG FORUM (PART IV)

    Speaker(s):

    • Guohua Zhang
      President and CEO
      Novast Laboratories Ltd., China
  • 3:30PM - 5:00PM (China Standard Time)

    Session 0108 How Multiple-Disciplinary Department in Authority Works Together Collaboratively to


    Session Chair(s):

    • Hengxu Wei
      Director, CMC Regulatory Affairs
      GSK, China

    Speaker(s):

    • The EU “Matrix”
      Evangelos Kotzagiorgis
      Scientific Administrator, Quality of Medicines, Human Medicines Evaluation Div
      European Medicine Agency, United Kingdom
    • China regulatory system on managing product quality
      Daniel Song
      Janssen Pharmaceutical Companies, Johnson & Johnson, China
  • 3:30PM - 5:00PM (China Standard Time)

    Session 0308 Project Management - Study Wide


    Session Chair(s):

    • Hualong Sun
      General manager
      Meta Clinical Technology, China

    Speaker(s):

    • CRO selection management
      Vivian Chang
      Shanghai Branch, Sanofi (China) Investment Co., Ltd., China
    • Challenges of Patients Enrollment and Compliance Management from Investigator Sites
      Wenchi Lin
      Sr Portfolio Director
      PAREXEL International, Taiwan
    • Challenges of Patients Enrollment and Compliance Management from Investigator Sites
      Laiping Zhong
      Professor, Department of Oral & Maxillofacial-Head & Neck Oncology
      Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, China
  • 3:30PM - 5:00PM (China Standard Time)

    Statistics & Data Management_ A joint venture towards high quality data collection, management and analysis Part 2


    Session Chair(s):

    • Charles Yan
      Senior Director, Data Management and Biometric
      Shanghai Hengrui Medicine Co, LTD, China

    Statistics & Data Management_ A joint venture towards high quality data collection, management and analysis Part 2

    Speaker(s):

    • Quality by Design_Carved in Data Management and Statistics
      Luyan Dai, PhD
      Associate Director, Biostatistics
      Boehringer Ingelheim, Shanghai, China
    • A Statistical Approach to Central Monitoring of Data Quality in Clinical Trials
      Tong Guo
      Head GDSA - Beijing Global Data Sciences & Analytics Beijing
      Bayer Healthcare Company Limited, China
  • 3:30PM - 5:00PM (China Standard Time)

    Session 0508 Herbs Safety


    Session Chair(s):

    • Hellen ZHANG Zhang
      Pharmacovigilance Country Head
      Bayer, China

    Speaker(s):

    • Understand and treat TCM safety properly
      Xuemin Gao
      Professor
      Beijing University of Chinese Medicine, China
    • Establishment and Practice of Pharmacovigilance System in Chinese Medicine Enterprise
      Hui Cao
      Director
      National Engineering Research Center, China
  • 3:30PM - 5:00PM (China Standard Time)

    Session 0908 Internationalization of Chinese CRO in china


    Session Chair(s):

    • Bin Li
      China

    Speaker(s):

    • Project Delivery Beauty-Project Manager-Empowerment
      Johnathan Lee
      Senior Director, Clinical Project Management,
      Quintiles Great China, China
    • Breakthrough Analytics within Clinical Trial Conduct
      David M. Kiger
      Vice President, Product Strategy
      PAREXEL Informatics , United States
    • Medical imaging in a keyrole to advance quality clinical trials
      Luxia Liang
      General Manager
      Fantastic Bioimaging Co. Ltd., China

Exhibits  

The 7th DIA China Annual Meeting offers interested companies the opportunity to rent a booth space in the Exhibit Hall.

Please see the below for additional information:

  • ACM Global Central Laboratory
  • ADICON Clinical Laboratory, Inc.
  • ArisGlobal KK
  • Barrington James
  • Beijing BioKnow Information Technology Co., Ltd.
  • Beijing Clinical Service Center
  • Beijing clinicalsoft Co., Ltd
  • Beijing CTSmed Co., Ltd.
  • Beijing Genwise Medicine Development Co., Ltd.
  • Beijing S&Q Healthcare Co., Ltd.
  • Beijing Vital River Laboratory Animal Technology Co., Ltd.
  • BioClinica
  • Blue Jidian Medical Science Co., Ltd.
  • Boon Pharmaceutical Research, Inc.
  • Brightech International
  • Cardinal Health China
  • Catalent Pharma Solutions
  • CCBR Clinical Research
  • Choice Pharma
  • City Express
  • Covance
  • CRScube Inc.
  • DIAN Medical Laboratory
  • EPS International
  • ERT Asia Group K.K.

Registration Fees 

Other Fees

Member Student
¥500.00
NonMember Student
¥700.00
Patient Advocate Rate
¥500.00
One Day Rate
¥2200.00

Member

Charitable Nonprofit/Academia Member
¥3500.00
Member Government
¥3500.00
Member Standard
¥5500.00

Non-Member

Charitable Nonprofit/Academia Nonmember
¥4500.00
NonMember Government
¥4500.00
NonMember Standard
¥6500.00
Registration Fees for Additional Offerings
Workshop 1: Essential Biostatistics Concepts Made Easy - Standard Rate
¥1200.00
Workshop 2: How to Complete a CDISC - Compliant CR - Standard Rate
¥2200.00
Workshop 3: Exploring Medical Communications Servi - Standard Rate
¥2200.00
Workshop 4: Lean: Innovative Approaches for Author - Standard Rate
¥2200.00
Register Online
« Back to Listing Back To Top